 |
Journal articles
Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.
Philippe Colombat
1, *
Nicole Brousse
2
Gilles Salles
3
Franck Morschhauser
4
Pauline Brice
5
Pierre Soubeyran
6
Vincent Delwail
7
Eric Deconinck
8
Corinne Haioun
9
Charles Foussard
10
Catherine Sebban
11
Hervé Tilly
12
Catherine Thieblemont
5
L. Bergougnoux
13
F. Lazreg
13
Philippe Solal-Celigny
14
*
Corresponding author
Philippe Colombat 1
Correspondent author
Nicole Brousse 2
Author
Gilles Salles 3
Author
Franck Morschhauser 4
Author
Catherine Thieblemont 5
Author
L. Bergougnoux 13
Author
F. Lazreg 13
Author
Philippe Solal-Celigny 14
Author
1
Service d'hématologie [Tours] (France)
2
Service d'anatomie pathologique [CHU Necker] (149 Rue de Sèvres, 75015 Paris - France)
- CHU Necker - Enfants Malades [AP-HP] (149 Rue de Sèvres 75015 Paris - France)
- AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) (France)
3
Service d'Hematologie (69495, Pierre-Benite Cedex - France)
- HCL - Hospices Civils de Lyon (3 Quai des Célestins 69002 Lyon - France)
- CHLS - Centre Hospitalier Lyon Sud [CHU - HCL] (165 Chemin du Grand Revoyet
69495 Pierre-Bénite - France)
- HCL - Hospices Civils de Lyon (3 Quai des Célestins 69002 Lyon - France)
4
Service d'hématologie (Lille - France)
- Hôpital Claude Huriez (France)
- CHRU Lille - Centre Hospitalier Régional Universitaire [Lille] (2, avenue Oscar Lambret - 59037 Lille Cedex - France)
5
Service d'hématologie-oncologie adultes (1, avenue Claude-Vellefaux 75475 PARIS Cedex 10 - France)
- AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) (France)
- UPD7 - Université Paris Diderot - Paris 7 (5 rue Thomas-Mann - 75205 Paris cedex 13 - France)
- Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris] (200 rue du Faubourg Saint-Denis 75475 Paris (Nord) Cedex 10 - France)
6
Plateforme de génétique moléculaire des cancers d'Aquitaine (Département de Bio-pathologie - 229 cours de l'Argonne 33076 Bordeaux cedex - France)
- Institut Bergonié [Bordeaux] (229, cours de l'Argonne - 33076 Bordeaux - France)
- UNICANCER (101, rue de Tolbiac, 75654 Paris Cedex 13 - France)
7
Service d'Anatomie et de Cytologie Pathologiques [Poitiers] (2 rue de la Milétrie BP 577, 86021 Poitiers Cedex - France)
- CHU Poitiers - Centre hospitalier universitaire de Poitiers (2 Rue de la Milétrie, 86021 Poitiers - France)
8
Service d'hématologie (France)
9
Service d'hématologie clinique (Créteil - France)
- AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) (France)
- Hôpital Henri Mondor (France)
- UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12 (61 avenue du Général de Gaulle - 94010 Créteil cedex - France)
10
Service d'hématologie (Angers - France)
- CHU Angers - Centre Hospitalier Universitaire d'Angers (4 rue Larrey - 49933 Angers cedex 9 - France)
- Hôtel Dieu (France)
11
Service d'Oncologie Médicale (Lyon - France)
- Centre Léon Bérard [Lyon] (28, rue Laennec 69373 LYON Cedex 08 - France)
Abstract : BACKGROUND: The purpose of this study was to report long-term results of rituximab induction monotherapy in patients with low-tumor-burden follicular lymphoma (LTBFL). PATIENTS AND METHODS: Of 49 first-line LTBFL patients who received weekly doses of rituximab (375 mg/m(2)), 46 have been followed with a long-term analysis of clinical and molecular responses. RESULTS: Best clinical response (at any staging within a year following treatment) was 80%, 24 (52%) patients had complete or unconfirmed complete response, 13 (28%) had partial response and 9 (20%) had stable or progressive disease. Of 31 patients having a positive bcl2-JH rearrangement, 15 (48%) became negative following treatment. After 83.9 months of follow-up (95% confidence interval 6.4-92.8 months), the median progression-free survival is 23.5 months and overall survival (OS) is 91.7%. Five patients died (one progression, one myelodysplasia, one diffuse large B-cell lymphoma and two solid tumors). Seven patients (15%) are progression-free including five who are bcl2 informative. No unexpected long-term adverse event has been observed. CONCLUSION: A significant proportion of patients remain progression-free 7 years after a single 4-dose rituximab treatment in first-line LTBFL. The 7-year overall survivalOS is very high in this selected population of patients.
Document type :
Journal articles
Domain :
Complete list of metadatas
https://www.hal.inserm.fr/inserm-00821113
Contributor : Philippe Saas <>
Submitted on : Tuesday, May 7, 2013 - 3:14:31 PM
Last modification on : Monday, August 31, 2020 - 9:52:05 AM
Contributor : Philippe Saas <>
Submitted on : Tuesday, May 7, 2013 - 3:14:31 PM
Last modification on : Monday, August 31, 2020 - 9:52:05 AM
Links full text
Identifiers
- HAL Id : inserm-00821113, version 1
- DOI : 10.1093/annonc/mds177
- PUBMED : 22782332
Collections
HCL | UNIV-PARIS7 | UNIV-PARIS5 | UPEC-UPEM | USPC | BERGONIE | FNCLCC | BECQUEREL | CHLS | UNAM | UPEC | UNIV-PARIS
Citation
Philippe Colombat, Nicole Brousse, Gilles Salles, Franck Morschhauser, Pauline Brice, et al.. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.. Annals of Oncology, Elsevier, 2012, 23 (9), pp.2380-5. ⟨10.1093/annonc/mds177⟩. ⟨inserm-00821113⟩
Metrics
Record views